Will a Phase 3 trial for a genital herpes vaccine be successful by end of 2025?
Yes • 50%
No • 50%
Press releases from major pharmaceutical companies
Over 846 Million Adults Aged 15-49 Live with Genital Herpes, 42 Million New Cases Annually
Dec 11, 2024, 03:27 AM
A recent survey highlights the widespread prevalence of genital herpes among individuals aged 15 to 49. According to the World Health Organization (WHO), over 846 million adults globally within this age group are living with the infection, which equates to more than one in five people. Additionally, there are 42 million new cases of genital herpes recorded annually. The sexually transmitted infection, which currently has no cure, underscores the need for advancements in vaccine development to address this global health challenge. More than 840 million people under age 50 are affected worldwide.
View original story
No • 50%
Yes • 50%
Unsuccessful • 25%
Successful with high efficacy • 25%
Successful with moderate efficacy • 25%
Trial inconclusive • 25%
No • 50%
Yes • 50%
Successful with FDA approval • 25%
Ongoing • 25%
Unsuccessful • 25%
Successful without FDA approval • 25%
Successful with FDA approval • 25%
Trial ongoing • 25%
Unsuccessful • 25%
Successful without FDA approval • 25%
HPV • 25%
HIV/AIDS • 25%
Other • 25%
Genital Herpes • 25%
Other • 25%
Moderna • 25%
GlaxoSmithKline • 25%
Pfizer • 25%